Table 1.
Characteristics of patients
| Women (%), n=166 | Men (%), n=287 | Total (%), n=453 | |
|---|---|---|---|
| Median survival, months (IQR) | 20 (9–44.8) | 21 (8–43) | 20 (9–44) |
| Year of diagnosis | |||
| 2004–2008 | 87 (52.4) | 150 (52.3) | 237 (52.3) |
| 2009–2013 | 79 (47.6) | 137 (47.7) | 216 (47.7) |
| Age at diagnosis, years | |||
| 0–54 | 30 (18.1) | 61 (21.3) | 91 (20.1) |
| 55–64 | 43 (25.9) | 59 (20.6) | 102 (22.5) |
| 65–74 | 42 (25.3) | 65 (22.6) | 107 (23.6) |
| 75–84 | 31 (18.7) | 70 (24.4) | 101 (22.3) |
| 85+ | 20 (12) | 32 (11.1) | 52 (11.5) |
| Race | |||
| White | 102 (61.4) | 236 (82.2) | 338 (74.6) |
| Black | 50 (30.1) | 35 (12.2) | 85 (18.8) |
| Others | 14 (8.4) | 16 (5.6) | 30 (6.6) |
| Marital status | |||
| Not married | 99 (59.6) | 88 (30.7) | 187 (41.3) |
| Married (including common law) | 58 (34.9) | 184 (64.1) | 242 (53.4) |
| Unknown | 9 (5.4) | 15 (5.2) | 24 (5.3) |
| Grade | |||
| Grade I and grade II | 58 (34.9) | 73 (25.4) | 131 (28.9) |
| Grade III | 63 (38) | 96 (33.4) | 159 (35.1) |
| Grade IV | 22 (13.3) | 67 (23.3) | 89 (19.6) |
| Unknown | 23 (13.9) | 51 (17.8) | 74 (16.3) |
| Tumor size, cm | |||
| ≤2 | 23 (13.9) | 26 (9.1) | 49 (10.8) |
| >2 and ≤5 | 40 (24.1) | 65 (22.6) | 105 (23.2) |
| >5 | 14 (8.4) | 34 (11.8) | 48 (10.6) |
| Unknown | 89 (53.6) | 162 (56.4) | 251 (55.4) |
| Positive-node status | |||
| 0 | 30 (18.1) | 25 (8.7) | 55 (12.1) |
| 1–3 | 22 (13.3) | 28 (9.8) | 50 (11) |
| >3 | 0 | 7 (2.4) | 7 (1.5) |
| Unknown | 114 (68.7) | 227 (79.1) | 341 (75.3) |
| AJCC stage | |||
| I | 38 (22.9) | 73 (25.4) | 111 (24.5) |
| II | 23 (13.9) | 56 (19.5) | 79 (17.4) |
| III and IV | 94 (56.6) | 119 (41.5) | 213 (47) |
| Unknown | 11 (6.6) | 39 (13.6) | 50 (11) |
| pT stage | |||
| T0 and T1 | 43 (25.9) | 91 (31.7) | 134 (29.6) |
| T2 | 31 (18.7) | 85 (29.6) | 116 (25.6) |
| T3 | 57 (34.3) | 44 (15.3) | 101 (22.3) |
| T4 and TX | 35 (21.1) | 67 (23.3) | 102 (22.5) |
| pN stage | |||
| N0 | 118 (71.1) | 195 (67.9) | 313 (69.1) |
| N1 | 21 (12.7) | 36 (12.5) | 57 (12.6) |
| N2 | 16 (9.6) | 26 (9.1) | 42 (9.3) |
| NX | 11 (6.6) | 30 (10.5) | 41 (9.1) |
| pM stage | |||
| M0 | 143 (86.1) | 234 (81.5) | 377 (83.2) |
| M1 | 17 (10.2) | 34 (11.8) | 51 (11.3) |
| MX | 6 (3.6) | 19 (6.6) | 25 (5.5) |
| Surgery | |||
| No | 60 (36.1) | 77 (26.8) | 137 (30.2) |
| Yes | 106 (63.9) | 210 (73.2) | 316 (69.8) |
| Radiation | |||
| Yes | 69 (41.6) | 67 (23.3) | 136 (30) |
| No | 97 (58.4) | 220 (76.7) | 317 (70) |
| Histological type | |||
| SCC, NOS | 52 (31.3) | 113 (39.4) | 165 (36.4) |
| TCC, NOS | 54 (32.5) | 148 (51.6) | 202 (44.6) |
| Ac, NOS | 60 (36.1) | 26 (9.1) | 86 (19) |
Abbreviations: AJCC, American Joint Committee on Cancer; SCC, squamous cell carcinoma; TCC, transitional cell carcinoma; Ac, adenocarcinoma; NOS, not otherwise specified.